enGene (NASDAQ:ENGN) Upgraded at Leerink Partners

Leerink Partners upgraded shares of enGene (NASDAQ:ENGN – Free Report) from a market perform rating to an outperform rating in a research note published on Friday, Marketbeat.com reports. Leerink Partners currently has $5.00 price target on the stock.

A number of other equities research analysts also recently weighed in on the company. Piper Sandler raised enGene from a “neutral” rating to an “overweight” rating and set a $4.00 price objective on the stock in a research report on Thursday. Citizens Jmp reiterated a “market perform” rating on shares of enGene in a report on Wednesday, September 9th. Weiss Ratings cut shares of enGene from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 30th. HC Wainwright reaffirmed a “buy” rating on shares of enGene in a research report on Friday, October 16th. Finally, Raymond James Financial reiterated an “outperform” rating on shares of enGene in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, enGene currently has an average rating of “Moderate Buy” and an average target price of $10.75.

View Our Latest Stock Report on enGene

enGene Stock Performance

Shares of NASDAQ:ENGN opened at $2.41 on Friday. The company has a market capitalization of $161.52 million, a price-to-earnings ratio of -1.16 and a beta of -0.24. enGene has a 52 week low of $1.40 and a 52 week high of $12.25. The company has a quick ratio of 10.21, a current ratio of 10.21 and a debt-to-equity ratio of 0.11. The firm has a 50 day moving average of $1.79 and a 200 day moving average of $3.97.

enGene (NASDAQ:ENGN – Get Free Report) last announced its earnings results on Tuesday, September 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.04). On average, sell-side analysts predict that enGene will post -1.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On enGene

Several hedge funds and other institutional investors have recently modified their holdings of ENGN. Siren L.L.C. grew its position in enGene by 57.5% during the 1st quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock worth $35,774,000 after purchasing an additional 1,916,895 shares during the last quarter. Eversept Partners LP lifted its stake in shares of enGene by 12.0% during the first quarter. Eversept Partners LP now owns 510,543 shares of the company’s stock worth $3,477,000 after buying an additional 54,708 shares during the period. Monashee Investment Management LLC grew its holdings in shares of enGene by 8.5% during the first quarter. Monashee Investment Management LLC now owns 320,000 shares of the company’s stock valued at $2,179,000 after buying an additional 25,000 shares during the last quarter. SR One Capital Management LP purchased a new stake in shares of enGene during the second quarter valued at $1,293,607. Finally, Renaissance Technologies LLC increased its position in shares of enGene by 651.1% in the 1st quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock valued at $1,063,000 after acquiring an additional 135,318 shares during the period. 64.16% of the stock is owned by hedge funds and other institutional investors.

About enGene

(Get Free Report)

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Recommended Stories

Analyst Recommendations for enGene (NASDAQ:ENGN)

Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.